Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Sales: 2013-2025

Historic Return on Sales for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to 0.27%.

  • Theravance Biopharma's Return on Sales rose 105.00% to 0.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.27%, marking a year-over-year increase of 105.00%. This contributed to the annual value of -0.99% for FY2024, which is 3.00% down from last year.
  • As of Q3 2025, Theravance Biopharma's Return on Sales stood at 0.27%, which was up 281.24% from 0.07% recorded in Q2 2025.
  • Theravance Biopharma's 5-year Return on Sales high stood at 24.10% for Q3 2022, and its period low was -3.09% during Q1 2021.
  • Moreover, its 3-year median value for Return on Sales was -0.74% (2024), whereas its average is 2.81%.
  • As far as peak fluctuations go, Theravance Biopharma's Return on Sales spiked by 2,470bps in 2022, and later tumbled by 2,489bps in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Return on Sales stood at 1.19% in 2021, then spiked by 2,255bps to 23.74% in 2022, then tumbled by 2,470bps to -0.96% in 2023, then fell by 3bps to -0.99% in 2024, then surged by 105bps to 0.27% in 2025.
  • Its Return on Sales was 0.27% in Q3 2025, compared to 0.07% in Q2 2025 and -1.01% in Q1 2025.